Cargando…

Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis

PURPOSE: Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. METHODS: CCK8 assay was used to measure cell viability rate of K562/ADR. Int...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenjing, Niu, Shubin, Qiao, Luxin, Wei, Feili, Yin, Jiming, Wang, Shanshan, Ouyang, Yabo, Chen, Dexi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388510/
https://www.ncbi.nlm.nih.gov/pubmed/30886864
http://dx.doi.org/10.1155/2019/8727935
_version_ 1783397778082234368
author Wang, Wenjing
Niu, Shubin
Qiao, Luxin
Wei, Feili
Yin, Jiming
Wang, Shanshan
Ouyang, Yabo
Chen, Dexi
author_facet Wang, Wenjing
Niu, Shubin
Qiao, Luxin
Wei, Feili
Yin, Jiming
Wang, Shanshan
Ouyang, Yabo
Chen, Dexi
author_sort Wang, Wenjing
collection PubMed
description PURPOSE: Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. METHODS: CCK8 assay was used to measure cell viability rate of K562/ADR. Intracellular reactive oxygen species (ROS) generation, cell cycle distribution, cell apoptosis were measured with flow cytometry, respectively. Proteins related to apoptosis were measured by Western blot. Intracellular Adriamycin accumulation was observed by confocal microscopy and measured by flow cytometry. RESULTS: In vitro study showed intracellular Adriamycin accumulation was remarkably increased by UA. Cell viability treated with Adr (4 μM) was decreased from 89.8%  ± 4.7 to 32%  ± 8.9 by combined with UA (4 μM). Adr-induced apoptosis and G(1)/G(0) phase cell cycle arrest were remarkably increased by UA, as well as, intracellular ROS level. However, MDR reversing activity of UA was inhibited by N-acetyl cysteine (NAC), a ROS scavenger. CONCLUSION: These data provide compelling evidence that UA is a promising agent against MDR in leukemia cell line and suggest a promising therapeutic approach for leukemia.
format Online
Article
Text
id pubmed-6388510
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63885102019-03-18 Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis Wang, Wenjing Niu, Shubin Qiao, Luxin Wei, Feili Yin, Jiming Wang, Shanshan Ouyang, Yabo Chen, Dexi Biomed Res Int Research Article PURPOSE: Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. METHODS: CCK8 assay was used to measure cell viability rate of K562/ADR. Intracellular reactive oxygen species (ROS) generation, cell cycle distribution, cell apoptosis were measured with flow cytometry, respectively. Proteins related to apoptosis were measured by Western blot. Intracellular Adriamycin accumulation was observed by confocal microscopy and measured by flow cytometry. RESULTS: In vitro study showed intracellular Adriamycin accumulation was remarkably increased by UA. Cell viability treated with Adr (4 μM) was decreased from 89.8%  ± 4.7 to 32%  ± 8.9 by combined with UA (4 μM). Adr-induced apoptosis and G(1)/G(0) phase cell cycle arrest were remarkably increased by UA, as well as, intracellular ROS level. However, MDR reversing activity of UA was inhibited by N-acetyl cysteine (NAC), a ROS scavenger. CONCLUSION: These data provide compelling evidence that UA is a promising agent against MDR in leukemia cell line and suggest a promising therapeutic approach for leukemia. Hindawi 2019-02-11 /pmc/articles/PMC6388510/ /pubmed/30886864 http://dx.doi.org/10.1155/2019/8727935 Text en Copyright © 2019 Wenjing Wang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Wenjing
Niu, Shubin
Qiao, Luxin
Wei, Feili
Yin, Jiming
Wang, Shanshan
Ouyang, Yabo
Chen, Dexi
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_full Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_fullStr Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_full_unstemmed Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_short Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_sort usnea acid as multidrug resistance (mdr) reversing agent against human chronic myelogenous leukemia k562/adr cells via an ros dependent apoptosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388510/
https://www.ncbi.nlm.nih.gov/pubmed/30886864
http://dx.doi.org/10.1155/2019/8727935
work_keys_str_mv AT wangwenjing usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT niushubin usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT qiaoluxin usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT weifeili usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT yinjiming usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT wangshanshan usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT ouyangyabo usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT chendexi usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis